09:39 AM EDT, 10/14/2025 (MT Newswires) -- Trinity Capital ( TRIN ) said Tuesday it will provide $130 million in growth capital to Candel Therapeutics ( CADL ) .

Trinity Capital's ( TRIN ) investment will be used to support Candel's clinical development of CAN-2409, along with pre-commercial and launch activities for CAN-2409 in prostate cancer, pending regulatory approval, Trinity Capital ( TRIN ) said.

Shares of Trinity Capital ( TRIN ) and Candel were down 0.6% and 4.5%, respectively, in recent early trading.

Price: 14.80, Change: -0.03, Percent Change: -0.20